Paul G. Richardson, MD, discusses phase 1 data (NCT03374085) with CC-92480 in multiple myeloma.
Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, and RJ Corman Professor of Medicine at Harvard Medical School, discusses phase 1 data (NCT03374085) with CC-92480 in multiple myeloma.
In an ongoing phase 1 trial, CC-92480 in combination with dexamethasone showed favorable activity and safety in patients with heavily pretreated relapsed/refractory multiple myeloma. The overall response rate was 21.1%.
At the time of data cutoff, approximately one-third of patients remained on study. The majority of treatment-related discontinuations were due to progressive disease, says Richardson. There have been no treatment-related deaths.
Dose-limiting toxicities, which included neutropenia and thrombocytopenia, were manageable with dose reductions, schedule modifications, and supportive care, says Richardson. The maximum-tolerated dose was determined to be 1 mg once daily.